Asarina Pharma reported its Q1'20 earnings this morning. But the real news took place after Q1 when the company announced top-line results from a phase IIb study in PMDD. Unfortunately, the results were inconclusive due to a high placebo response rate. Redeye is now working on gaining a better perception of the prospects for sepranolone in MM and TS, as our primary focus, until a month ago, has been PMDD.